Dual-domain peptide for depleting HMGB1 from the circulation via liver HSPG system
The dual-domain peptide hE-HMGB1-BP and associated inhibitors target HMGB1 and GSNOR pathways to address SCD-induced vasculopathy and lung disease, improving vasodilation and lung function by reducing HMGB1 levels and inhibiting inflammatory and oxidative stress mechanisms.
Patent Information
- Application Number
- PCT/US2024/028808
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-02
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
Sickle cell disease (SCD) causes vasculopathy and chronic lung disease through mechanisms involving high mobility group box-1 (HMGB1) and S-nitrosoglutathione reductase (GSNOR), which impair vasodilation and increase chronic lung injury by reducing nitric oxide bioavailability.
A dual-domain peptide, hE-HMGB1-BP, is designed to bind and deplete HMGB1 from circulation via the liver's heparin sulfate proteoglycan system, and N-acetyl-lysyltyrosylcysteine amide (KYC) is used to inhibit myeloperoxidase-initiated and HMGB1-propagated inflammatory pathways, while N6022 inhibits GSNOR to restore vasodilation and improve lung morphometries.
The approach effectively reduces HMGB1 levels, improves endothelial and eNOS-dependent vasodilation, decreases liver injury, and enhances lung protein S-nitrosylation, thereby alleviating SCD-induced vasculopathy and chronic lung injury by targeting HMGB1 and GSNOR pathways.
Smart Images

Figure 000047 
Figure 000048 
Figure 000049
Abstract
Citation Information
Patent Citations
Peptide-Based Peroxidase Inhibitors and Methods of Using Same
US20140194342A1
Apoe mimetic peptides and higher potency to clear plasma cholesterol
US20170209537A1
